1SettimanaΒ·

$ABBV (+1,65%)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (+0,32%) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commenti

Should it go down another 10%-15% at $ABBV: πŸ›’πŸ›’πŸ›’πŸ›’
β€’
9
β€’
immagine del profilo
1Settimana
If AbbVie goes down even further, I might spontaneously get in today ^^
β€’
3
β€’
Visualizza tutti 4 ulteriori risposte
immagine del profilo
Am in
β€’
2
β€’
immagine del profilo
Hach, 30% at $BMY in 6 months. I can live with that πŸ₯³πŸ˜Ž
β€’
2
β€’
immagine del profilo
stupid :(
β€’β€’
immagine del profilo
1Settimana
Gut :)
β€’β€’
1Settimana
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... πŸ€·β€β™€οΈ is this a known error or what is the reason for this? πŸ€·β€β™€οΈ
β€’β€’
Partecipa alla conversazione